Two Sigma Advisers LP Cuts Position in Humana Inc. (NYSE:HUM)

Two Sigma Advisers LP cut its stake in shares of Humana Inc. (NYSE:HUM - Free Report) by 13.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 906,280 shares of the insurance provider's stock after selling 137,300 shares during the quarter. Two Sigma Advisers LP owned 0.75% of Humana worth $229,932,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Assenagon Asset Management S.A. increased its stake in shares of Humana by 21.5% during the fourth quarter. Assenagon Asset Management S.A. now owns 4,969 shares of the insurance provider's stock worth $1,261,000 after acquiring an additional 879 shares during the period. Merit Financial Group LLC raised its stake in shares of Humana by 16.6% during the 4th quarter. Merit Financial Group LLC now owns 1,819 shares of the insurance provider's stock worth $461,000 after buying an additional 259 shares in the last quarter. Clarius Group LLC raised its stake in shares of Humana by 7.0% during the 4th quarter. Clarius Group LLC now owns 905 shares of the insurance provider's stock worth $230,000 after buying an additional 59 shares in the last quarter. Liberty One Investment Management LLC acquired a new stake in shares of Humana in the 4th quarter valued at approximately $822,000. Finally, Willner & Heller LLC boosted its stake in shares of Humana by 28.2% in the fourth quarter. Willner & Heller LLC now owns 2,002 shares of the insurance provider's stock valued at $508,000 after buying an additional 440 shares in the last quarter. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Humana Trading Down 1.0%

Humana stock traded down $2.33 during trading on Friday, hitting $224.81. The company's stock had a trading volume of 1,406,034 shares, compared to its average volume of 1,781,205. The stock's fifty day moving average is $262.07 and its 200 day moving average is $269.01. Humana Inc. has a 1-year low of $212.45 and a 1-year high of $406.46. The stock has a market capitalization of $27.13 billion, a price-to-earnings ratio of 22.59, a P/E/G ratio of 2.05 and a beta of 0.49. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.76 and a current ratio of 1.76.

Humana (NYSE:HUM - Get Free Report) last posted its quarterly earnings data on Wednesday, April 30th. The insurance provider reported $11.58 EPS for the quarter, beating analysts' consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion during the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. The company's quarterly revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $7.23 EPS. As a group, equities research analysts predict that Humana Inc. will post 16.47 EPS for the current year.

Humana Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be paid a dividend of $0.885 per share. This represents a $3.54 dividend on an annualized basis and a yield of 1.57%. The ex-dividend date is Friday, June 27th. Humana's dividend payout ratio is currently 25.04%.

Analyst Ratings Changes

A number of equities research analysts have commented on the company. Barclays raised their target price on Humana from $270.00 to $322.00 and gave the company an "equal weight" rating in a report on Friday, April 11th. Guggenheim began coverage on shares of Humana in a report on Wednesday, April 9th. They set a "buy" rating and a $326.00 price objective on the stock. Truist Financial lowered their target price on shares of Humana from $325.00 to $305.00 and set a "hold" rating on the stock in a research report on Monday, May 12th. Robert W. Baird boosted their price target on Humana from $270.00 to $300.00 and gave the stock a "neutral" rating in a research note on Tuesday, April 15th. Finally, Mizuho raised their price objective on Humana from $305.00 to $316.00 and gave the company an "outperform" rating in a research note on Wednesday, April 9th. Seventeen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company's stock. According to data from MarketBeat, the company currently has an average rating of "Hold" and a consensus price target of $286.81.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.